Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya3368710.26442/00403660.2019.09.000192Editorial articleПередовая статьяReview ArticleRisk stratification methods and their significance in pulmonary arterial hypertensionМетоды стратификации рисков и их значение при легочной артериальной гипертензииAvdeevS NАвдеевСергей Николаевич

д.м.н., проф., член-корр. РАН, зав. каф. пульмонологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет); руководитель клинического отд. ФГБУ «НИИ пульмонологии» ФМБА России; ORCID: 0000-0002-5999-2150

TsarevaN AЦареваНаталья Анатольевна

к.м.н., доцент каф. пульмонологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет); зав. лаб. интенсивной пульмонологии и дыхательной недостаточности ФГБУ «НИИ пульмонологии» ФМБА России; ORCID: 0000-0001-9357-4924

n_tsareva@mail.ruSechenov First Moscow State Medical University (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)Pulmonology Research InstituteФГБУ «Научно-исследовательский институт пульмонологии» ФМБА России15092019919VOL 91, NO9 (2019)ТОМ 91, №9 (2019)15015716042020Copyright ©; 2019, Consilium MedicumCopyright ©; 2019, ООО "Консилиум Медикум"2019Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/33687

Despite significant advances in therapy, pulmonary arterial hypertension (PAH) remains a progressive disease with a poor prognosis. Immediately after establishing the diagnosis of PAH, urgent treatment with PAH-specific therapy is required. Due to the progressive nature of the disease, all patients should be closely monitored and their treatment regimen should be promptly changed according to clinical need. Risk stratification is an important method for informing the clinician and the patient about the prognosis of disease and the choice of therapy methods. The REVEAL scale and the ESC/ERS 2015 risk assessment table are important multifactorial tools for making decisions about the prescription and correction of PAH therapy, as well as for assessment of patients' response to therapy. Current guidelines for PAH indicate that the most important task of treatment of PAH is to achieve the low - risk status.

Несмотря на значительные достижения в области терапии, легочная артериальная гипертензия (ЛАГ), по - прежнему, остается прогрессирующим заболеванием с неблагоприятным прогнозом. Сразу после установления диагноза ЛАГ требуется безотлагательное назначение ЛАГ-специфической терапии. В связи с прогрессирующим характером заболевания, все пациенты должны находиться под пристальным наблюдением, и их режим лечения должен своевременно меняться в соответствии с клинической необходимостью. Стратификация рисков ЛАГ является важным методом для информирования клинициста и пациента о прогнозе, выборе методов терапии. Шкала REVEAL и таблица оценки рисков ESC/ERS 2015 г. являются важными мультифакторными инструментами для принятия решений о назначении и коррекции терапии ЛАГ, а также для оценки ответа пациентов на терапию. Наиболее важной задачей терапии ЛАГ является достижение статуса низкого риска, что нашло отражение в современных рекомендациях по ЛАГ.

pulmonary arterial hypertensionrisk stratificationPAH specific therapycombination therapyлегочная артериальная гипертензиястратификация рисковЛАГ специфическая терапиякомбинированная терапияGaliè N, Humbert M, Vachiery J.L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J. 2015;46:903-75.Чазова И.Е., Авдеев С.Н., Царева Н.А., Волков А.В., Мартынюк Т.В., Наконечников С.Н. Клинические рекомендации по диагностике и лечению легочной гипертонии. Терапевтический архив. 2014;86(9):4-23.Simonneau G, Hoeper M.M, Mc Laughlin V, et al. Future perspectives in pulmonary arterial hypertension. Eur Respir Rev. 2016;25:381-9.Weatherald J, Boucly A, Sitbon O. Risk stratification in pulmonary arterial hypertension. Curr Opin Pulm Med. 2018;24:407-15.Weatherald J, Sitbon O, Humbert M. Validation of a risk assessment instrument for pulmonary arterial hypertension. Eur Heart J. 2018;39:4182-5.Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen - associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156-63.Benza R.L, Miller D.P, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122:164-72.Condliffe R, Kiely D.G, Peacock A.J, et al. Connective tissue disease - associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179:151-7.Chung L, Farber H.W, Benza R, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest. 2014;146:1494-504.Rubenfire M, Huffman M.D, Krishnan S, et al. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era. Chest. 2013;144:1282-90.Evans J.D.W, Girerd B, Montani D, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta - analysis. Lancet Respir Med. 2016;4:129-37.Mc Laughlin V.V, Gaine S.P, Howard L.S, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol. 2013;62:73-81.Sitbon O, Humbert M, Nunes H, et al. Long - term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-8.Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-min walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta - analysis of 22 randomized trials. J Am Coll Cardiol. 2012;60:1192-201.Wensel R, Opitz C.F, Anker S.D, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106:319-24.Wensel R, Francis D.P, Meyer F.J, et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonaryarterial hypertension. Int J Cardiol. 2013;167:1193-8.Badagliacca R, Papa S, Valli G, et al. Echocardiography combined with cardiopulmonary exercise testing for the prediction of outcome in idiopathic pulmonary arterial hypertension. Chest. 2016;150:1313-22.Groepenhoff H, Vonk-Noordegraaf A, Boonstra A, et al. Exercise testing to estimate survival in pulmonary hypertension. Med Sci Sports Exerc. 2008;40:1725-32.Schwaiblmair M, Faul C, von Scheidt W, Berghaus T.M. Ventilatory efficiency testing as prognostic value in patients with pulmonary hypertension. BMC Pulm Med. 2012;12:23.Benza R.L, Gomberg-Maitland M, Miller D.P, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141:354-62.Mauritz G-J, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial Nterminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol. 2011;108:1645-50.Frantz R.P, Farber H.W, Badesch D.B, et al. Baseline and serial brain natriuretic peptide level predicts 5-year overall survival in patients with pulmonary arterial hypertension: data from the REVEAL registry. Chest. 2018;154:126-35.Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow - up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39:589-96.Mathai S.C, Bueso M, Hummers L.K, et al. Disproportionate elevation of Nterminal pro - brain natriuretic peptide in scleroderma - related pulmonary hypertension. Eur Respir J. 2010;35:95-104.Bourji K.I, Hassoun P.M. Right ventricle dysfunction in pulmonary hypertension: mechanisms and modes of detection. Curr Opin Pulm Med. 2015;21:446-53.Weatherald J, Boucly A, Chemla D, et al. Prognostic value of follow - up hemodynamic variables after initial management in pulmonary arterial hypertension. Circulation. 2018;137:693-704.Van Wolferen S.A, Marcus J.T, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007;28:1250-7.Fine N.M, Chen L, Bastiansen P.M, et al. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. Circ Cardiovasc Imaging. 2013;6:711-21.Mazurek J.A, Vaidya A, Mathai S.C, et al. Follow - up tricuspid annular plane systolic excursion predicts survival in pulmonary arterial hypertension. Pulm Circ. 2017;7:361-71.Forfia P.R, Fisher M.R, Mathai S.C, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174:1034-41.Austin C, Alassas K, Burger C, et al. Echocardiographic assessment of estimated right atrial pressure and size predicts mortality in pulmonary arterial hypertension. Chest. 2015;147:198-208.Swift A.J, Capener D, Johns C, et al. Magnetic resonance imaging in the prognostic evaluation of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2017;196:228-39.Baggen V.J.M, Leiner T, Post M.C, et al. Cardiac magnetic resonance findings predicting mortality in patients with pulmonary arterial hypertension: a systematic review and meta - analysis. Eur Radiol. 2016;26:3771-80.Courand P-Y, Pina Jomir G, Khouatra C, et al. Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension. Eur Respir J. 2015;45:139-49.Van de Veerdonk M.C, Marcus J.T, Westerhof N, et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest. 2015;147:1063-71.D’Alonzo G.E, Barst R.J, Ayres S.M, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343-9.Humbert M, Sitbon O, Yaıci A, et al. French Pulmonary Arterial Hypertension Network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36:549-55.Thenappan T, Shah S.J, Rich S, et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010;35:1079-87.Thenappan T, Glassner C, Gomberg-Maitland M. Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Chest. 2012;141:642-50.Weatherald J, Boucly A, Sahay S, et al. The low - risk profile in pulmonary arterial hypertension. Time for a paradigm shift to goal - oriented clinical trial endpoints? Am J Respir Crit Care Med. 2018;197:860-8.Kane G.C, Maradit-Kremers H, Slusser J.P, et al. Integration of clinical and hemodynamic parameters in the prediction of long - term survival in patients with pulmonary arterial hypertension. Chest. 2011;139:1285-93.Benza R.L, Miller D.P, Foreman A.J, et al. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. J Heart Lung Transplant. 2015;34:356-61.Sitbon O, Benza R.L, Badesch D.B, et al. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J. 2015;46:152-64.Cogswell R, Pritzker M, De Marco T. Performance of the REVEAL pulmonary arterial hypertension prediction model using noninvasive and routinely measured parameters. J Heart Lung Transplant. 2014;33:382-7.Benza R.L, Elliott C.G, Farber H.W, et al. Updated risk score calculator for pulmonary arterial hypertension patients. J Heart Lung Transplant. 2017;36:S19.Kylhammar D, Kjellstrom B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow - up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39:4175-81.Hoeper M.M, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50:1700740.Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50:1700889.Hoeper M.M, Pittrow D, Opitz C, et al. Risk assessment in pulmonary arterial hypertension. Eur Respir J. 2018;51:1702606.Bartenstein P, Saxer S, Appenzeller P, et al. Risk factor profiles achieved with medical therapy in prevalent patients with pulmonary arterial and distal chronic thromboembolic pulmonary hypertension. Respiration. 2018;96:127-37.Gaine S, Mc Laughlin V. Pulmonary arterial hypertension: tailoring treatment to risk in the current era. Eur Respir Rev. 2017;26:170095.Sitbon O, Gaine S. Beyond a single pathway: combination therapy in pulmonary arterial hypertension. Eur Respir Rev. 2016;25:408-17.Pulido T, Adzerikho I, Channick R, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809-18.Sitbon O, Channick R, Chin K.M, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522-33.Galiè N, Barberà J.A, Frost A.E, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834-44.Sitbon O, Vonk Noordegraaf A. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience. Eur Respir Rev. 2017;26:160055.